High-risk medicines UK Medical PG Practice Questions and MCQs
Practice UK Medical PG questions for High-risk medicines. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
High-risk medicines UK Medical PG Question 1: A 28-year-old woman presents with a 3-day history of dysuria, urinary frequency, and suprapubic pain. She is otherwise well with no fever. Urine dipstick shows nitrites positive, leucocytes positive. What is the most appropriate first-line antibiotic treatment?
- A. Amoxicillin 500mg TDS for 7 days
- B. Trimethoprim 200mg BD for 3 days (Correct Answer)
- C. Ciprofloxacin 500mg BD for 7 days
- D. Nitrofurantoin 50mg QDS for 3 days
- E. Co-amoxiclav 625mg TDS for 7 days
High-risk medicines Explanation: ***Trimethoprim 200mg BD for 3 days***- This is a standard, highly effective **short course** regimen (3 days) recommended for community-acquired, uncomplicated **cystitis** in non-pregnant women, provided local **E. coli** resistance rates are acceptable (typically <20%).- Short courses improve adherence and minimize **collateral damage** (disruption of normal flora) and secondary resistance compared to longer courses.*Amoxicillin 500mg TDS for 7 days*- Amoxicillin monotherapy is unsuitable as first-line treatment for UTIs due to extremely high rates of **E. coli resistance** globally and poor efficacy in many regions.- The 7-day duration is unnecessarily long for uncomplicated **cystitis**, increasing antibiotic exposure and the risk of adverse effects.*Ciprofloxacin 500mg BD for 7 days*- **Fluoroquinolones** (like Ciprofloxacin) are generally reserved for complicated UTIs, **pyelonephritis**, or cases where first-line agents fail, due to resistance concerns and potential serious side effects.- A 7-day course is excessive. Uncomplicated cystitis usually requires only 3–5 days of effective therapy; 7 days is more appropriate for treating **pyelonephritis**.*Nitrofurantoin 50mg QDS for 3 days*- **Nitrofurantoin** is a preferred first-line agent, but the standard recommended regimen is typically 100mg BD for 5 days (or 50mg QDS for 5–7 days).- While highly effective against E. coli, a 3-day course of Nitrofurantoin is less established compared to the standard 3-day course used for **Trimethoprim** for uncomplicated cystitis.*Co-amoxiclav 625mg TDS for 7 days*- **Co-amoxiclav** (Amoxicillin/Clavulanate) is not a first-line agent for uncomplicated cystitis as it is a broad-spectrum antibiotic and increases the risk of **Clostridioides difficile infection** (CDI).- The 7-day duration is unnecessarily prolonged for treating simple **cystitis** in this patient, contributing to antibiotic selection pressure.
High-risk medicines UK Medical PG Question 2: A 59-year-old man with type 1 diabetes for 25 years is admitted with acute pancreatitis. His usual insulin regimen is insulin glargine 32 units at bedtime and insulin lispro 8 units with meals. He is kept nil by mouth and started on intravenous fluids. His admission glucose is 16.2 mmol/L. According to best practice for managing insulin in acute illness with nil-by-mouth status, what is the most appropriate insulin management?
- A. Continue insulin glargine at usual dose; omit insulin lispro while nil by mouth (Correct Answer)
- B. Continue insulin glargine; give insulin lispro based on blood glucose readings every 4 hours
- C. Stop all insulin until he is eating and drinking again
- D. Convert to variable-rate intravenous insulin infusion at 0.05 units/kg/hour
- E. Give half the usual total daily insulin dose as basal insulin only
High-risk medicines Explanation: ***Continue insulin glargine at usual dose; omit insulin lispro while nil by mouth***
- Patients with **Type 1 diabetes** have an absolute insulin deficiency and require continuous **basal insulin** (glargine) to prevent the development of **diabetic ketoacidosis (DKA)**, even when not eating.
- **Prandial insulin** (lispro) should be omitted while the patient is **nil by mouth** (NBM) to avoid hypoglycemia, as it is designed to cover carbohydrate intake.
*Continue insulin glargine; give insulin lispro based on blood glucose readings every 4 hours*
- While **glargine** must continue, scheduled **lispro** is for mealtime coverage; giving it every 4 hours without food intake significantly increases the risk of severe **hypoglycemia**.
- High blood glucose readings in an NBM patient should be managed with specific **correction doses** or a variable-rate intravenous insulin infusion if clinically indicated, not routine prandial boluses.
*Stop all insulin until he is eating and drinking again*
- Stopping all insulin in a Type 1 diabetic is dangerous and will lead to **diabetic ketoacidosis (DKA)** within hours because basal insulin is essential to suppress hepatic glucose production and **ketogenesis**.
- Total cessation of insulin is a common clinical error that must be avoided in **Type 1 diabetes** management during acute illness, regardless of nutritional status.
*Convert to variable-rate intravenous insulin infusion at 0.05 units/kg/hour*
- **Variable-rate intravenous insulin infusion (VRIII)** is typically reserved for metabolically unstable patients (e.g., DKA, severe hyperglycemia, major surgery, critical illness).
- For a stable NBM patient with Type 1 diabetes, continuing their **usual subcutaneous basal insulin** is generally preferred as it is simpler and maintains a steady physiological insulin level.
*Give half the usual total daily insulin dose as basal insulin only*
- Arbitrarily reducing the **basal insulin dose** by half risks insufficient insulin coverage, potentially leading to **hyperglycemia** and metabolic decompensation, especially during acute stress.
- The **standard dose of basal insulin** should generally be maintained in Type 1 diabetics to reflect their continuous physiological requirements and prevent DKA.
High-risk medicines UK Medical PG Question 3: A 68-year-old woman with non-valvular atrial fibrillation (CHA₂DS₂-VASc score 4) is on apixaban 5mg twice daily. She is diagnosed with intermediate-risk myelodysplastic syndrome requiring treatment with azacitidine chemotherapy, which carries significant thrombocytopenia risk (expected platelet nadir 20-50 × 10⁹/L). What is the most appropriate anticoagulation strategy during chemotherapy?
- A. Continue apixaban 5mg twice daily throughout chemotherapy; monitor platelets weekly
- B. Reduce apixaban to 2.5mg twice daily during chemotherapy cycles
- C. Switch to prophylactic-dose LMWH during chemotherapy cycles
- D. Switch to warfarin with target INR 2-3 as it can be more easily reversed
- E. Temporarily stop all anticoagulation during chemotherapy cycles; restart when platelets >50 × 10⁹/L (Correct Answer)
High-risk medicines Explanation: ***Temporarily stop all anticoagulation during chemotherapy cycles; restart when platelets >50 × 10⁹/L***
- For patients with **thrombocytopenia**, the bleeding risk from therapeutic anticoagulation significantly outweighs the stroke prevention benefit when the **platelet count drops below 50 × 10⁹/L**.
- This strategy minimizes the risk of **life-threatening hemorrhage** during the anticipated chemotherapy-induced nadir while allowing for the resumption of protection once platelets recover.
*Continue apixaban 5mg twice daily throughout chemotherapy; monitor platelets weekly*
- Maintaining full-dose **DOAC therapy** with a platelet count between 20-50 × 10⁹/L carries an unacceptably high risk of **major bleeding**.
- Weekly monitoring is insufficient to prevent acute bleeding events when severe **platelet suppression** is actively occurring due to cytotoxic agents.
*Reduce apixaban to 2.5mg twice daily during chemotherapy cycles*
- Dose reduction of **apixaban** is only indicated for specific criteria (age ≥80, weight ≤60kg, or creatinine ≥133 μmol/L); reducing it for **thrombocytopenia** is not evidence-based.
- A reduced dose may still cause significant bleeding at low platelet levels while providing **sub-therapeutic stroke prevention**.
*Switch to prophylactic-dose LMWH during chemotherapy cycles*
- **Prophylactic-dose LMWH** is inadequate for stroke prevention in a patient with a high **CHA₂DS₂-VASc score** of 4.
- In the setting of severe thrombocytopenia, even low-dose anticoagulation is often contraindicated until platelets reach a safer threshold.
*Switch to warfarin with target INR 2-3 as it can be more easily reversed*
- **Warfarin** is notoriously difficult to manage during chemotherapy due to **drug-nutrient interactions**, nausea, and fluctuating liver function.
- The risk of **intracranial hemorrhage** is significantly higher with warfarin compared to DOACs, especially when **platelet counts** are unstable.
High-risk medicines UK Medical PG Question 4: A 55-year-old woman with type 2 diabetes is on insulin detemir 38 units at 22:00 and metformin 1g twice daily. Her blood glucose readings show: fasting 6-8 mmol/L, pre-lunch 12-15 mmol/L, pre-dinner 10-13 mmol/L, bedtime 8-10 mmol/L. HbA1c is 68 mmol/mol (8.4%). Understanding insulin pharmacodynamics, what is the most appropriate next step in optimizing her insulin regimen?
- A. Split insulin detemir to twice-daily dosing (20 units morning, 20 units evening)
- B. Increase insulin detemir to 44 units at 22:00
- C. Add prandial rapid-acting insulin with main meals (Correct Answer)
- D. Switch from insulin detemir to insulin glargine
- E. Add a GLP-1 receptor agonist
High-risk medicines Explanation: ***Add prandial rapid-acting insulin with main meals***
- The patient's **fasting glucose** is within target (6-8 mmol/L), indicating the current **basal insulin** dose effectively covers overnight hepatic glucose production.
- The significant elevation in **pre-lunch** and **pre-dinner** readings demonstrates inadequate coverage of **post-prandial glucose excursions**, necessitating a **basal-bolus** regimen.
*Split insulin detemir to twice-daily dosing (20 units morning, 20 units evening)*
- Splitting the dose is typically used when **basal insulin** does not last 24 hours, leading to rising glucose before the next dose, which is not the case here given the stable **fasting readings**.
- This adjustment would not provide the rapid peaks required to control **meal-related glucose spikes** seen in this patient.
*Increase insulin detemir to 44 units at 22:00*
- Increasing the **basal dose** when fasting levels are already at target (6-8 mmol/L) significantly increases the risk of **nocturnal hypoglycemia**.
- Basal insulin is designed to manage background levels and is inefficient at controlling high **post-prandial hyperglycemia**.
*Switch from insulin detemir to insulin glargine*
- Both are **long-acting basal analogues**; switching between them primarily addresses duration of action or injection site reactions rather than **post-prandial control**.
- Glargine would still provide a relatively **flat peakless profile**, failing to address the 12-15 mmol/L spikes seen during the day.
*Add a GLP-1 receptor agonist*
- While **GLP-1 receptor agonists** help with post-prandial glucose and weight, the clinical priority for a patient already on significant insulin with an **HbA1c of 8.4%** is often rapid titration via a **basal-bolus** insulin strategy.
- In the context of "optimizing her **insulin regimen**," adding a rapid-acting bolus is the standard pharmacodynamic escalation to match mealtime carbohydrates.
High-risk medicines UK Medical PG Question 5: A 64-year-old man with atrial fibrillation is on rivaroxaban 20mg once daily. He requires emergency laparotomy for perforated diverticulitis within 2 hours. He took his last dose of rivaroxaban 8 hours ago. His renal function shows eGFR 58 ml/min/1.73m². Pre-operative blood tests show Hb 118 g/L. What is the most appropriate management of his anticoagulation?
- A. Give 4-factor prothrombin complex concentrate 50 units/kg before surgery (Correct Answer)
- B. Proceed to surgery; accept increased bleeding risk as surgery is life-saving
- C. Give fresh frozen plasma 15 ml/kg before surgery
- D. Delay surgery 12 hours to allow rivaroxaban clearance
- E. Give tranexamic acid 1g IV before surgery
High-risk medicines Explanation: ***Give 4-factor prothrombin complex concentrate 50 units/kg before surgery***
- For life-threatening emergency surgery in patients taking **Direct Oral Anticoagulants (DOACs)** like **rivaroxaban**, reversal is required to prevent catastrophic bleeding; **4-factor PCC** (50 units/kg) is recommended when specific antidotes like andexanet alfa are unavailable.
- Given the patient's **eGFR of 58 ml/min** and that the last dose was only **8 hours ago**, significant anticoagulant activity remains as the half-life of rivaroxaban is approximately 5–9 hours.
*Proceed to surgery; accept increased bleeding risk as surgery is life-saving*
- Proceeding without reversal in a major abdominal surgery like a **laparotomy** carries an unacceptably high risk of **uncontrolled intraoperative hemorrhage**.
- Standard of care mandates attempting to restore **hemostasis** before high-risk emergency procedures when the patient is fully anticoagulated.
*Give fresh frozen plasma 15 ml/kg before surgery*
- **Fresh frozen plasma (FFP)** is ineffective for reversing the effects of **Factor Xa inhibitors** because it lacks the concentration of clotting factors needed to overwhelm the drug effect.
- Using FFP would require **large volumes** to provide even minimal pro-coagulant effect, risking fluid overload without providing adequate reversal.
*Delay surgery 12 hours to allow rivaroxaban clearance*
- **Perforated diverticulitis** is a surgical emergency where delay increases the risk of **fecal peritonitis**, severe **sepsis**, and mortality.
- Anticoagulation should be reversed pharmacologically rather than waiting for **metabolic clearance** when the clinical situation is time-critical.
*Give tranexamic acid 1g IV before surgery*
- **Tranexamic acid** is an **antifibrinolytic** agent that prevents the breakdown of clots; it does not neutralize the **Factor Xa inhibition** caused by rivaroxaban.
- While it may be used as an adjunct, it is not a sufficient primary management strategy for **reversing anticoagulant effects** in an emergency.
High-risk medicines UK Medical PG Question 6: A 46-year-old man with type 1 diabetes for 20 years presents with a 3-month history of unpredictable blood glucose control despite good insulin adherence. He reports that his hypoglycaemic episodes now occur without warning symptoms. Investigations show HbA1c 58 mmol/mol (7.5%) but frequent hypoglycaemia on continuous glucose monitoring. What is the most appropriate modification to his insulin regimen?
- A. Switch to insulin pump therapy with continuous glucose monitoring
- B. Increase overall insulin doses to improve HbA1c
- C. Relax blood glucose targets and accept higher HbA1c to restore hypoglycaemia awareness (Correct Answer)
- D. Add acarbose to slow carbohydrate absorption
- E. Switch from rapid-acting to regular insulin analogues
High-risk medicines Explanation: ***Relax blood glucose targets and accept higher HbA1c to restore hypoglycaemia awareness***
- This patient presents with **impaired awareness of hypoglycaemia (IAH)**, characterized by the absence of warning symptoms during hypoglycaemic episodes, which is a significant safety concern.
- The primary treatment for IAH involves **strict avoidance of hypoglycaemia** for several weeks by intentionally raising blood glucose targets, allowing the **autonomic counter-regulatory responses** to re-establish.
*Switch to insulin pump therapy with continuous glucose monitoring*
- While **insulin pump therapy (CSII)** and **continuous glucose monitoring (CGM)** are valuable tools for tight glucose management and can help detect hypoglycaemia, they do not directly restore **hypoglycaemia awareness**.
- The immediate priority is to modify the patient's physiological response to low glucose, which requires a period free from hypoglycaemia, regardless of the delivery method or monitoring technology.
*Increase overall insulin doses to improve HbA1c*
- Increasing insulin doses in a patient experiencing **frequent, unwarned hypoglycaemia** would be dangerous, significantly increasing the risk of **severe hypoglycaemic events** and further worsening IAH.
- Although the HbA1c is 7.5%, safety takes precedence; aggressively lowering HbA1c in this scenario would compromise patient well-being by inducing more hypoglycaemia.
*Add acarbose to slow carbohydrate absorption*
- **Acarbose** is an alpha-glucosidase inhibitor primarily used in type 2 diabetes to reduce **postprandial glucose excursions** by delaying carbohydrate absorption in the gut.
- It has no role in the management of type 1 diabetes or in restoring **hypoglycaemia awareness**, and its use could complicate the rapid absorption of glucose needed for hypoglycaemia treatment.
*Switch from rapid-acting to regular insulin analogues*
- **Rapid-acting insulin analogues** are generally preferred in type 1 diabetes as they offer a quicker onset and shorter duration, better mimicking physiological insulin release and providing more flexible dosing.
- Switching to **regular insulin** would introduce a slower onset and longer action profile, increasing the risk of **delayed postprandial hypoglycaemia** and making mealtime insulin adjustments more challenging.
High-risk medicines UK Medical PG Question 7: A 58-year-old woman with atrial fibrillation is on edoxaban 60mg once daily. She develops acute bacterial endocarditis affecting the mitral valve and requires valve replacement surgery in 48 hours. Current renal function shows eGFR 65 ml/min/1.73m². What is the most appropriate approach to managing her anticoagulation perioperatively?
- A. Continue edoxaban until 24 hours before surgery, then restart 6 hours post-operatively
- B. Stop edoxaban 48 hours before surgery, bridge with LMWH, restart edoxaban post-operatively
- C. Stop edoxaban now, give PCC for reversal, start warfarin post-operatively with LMWH bridge (Correct Answer)
- D. Stop edoxaban now, start intravenous heparin infusion, restart edoxaban post-operatively
- E. Stop edoxaban now, no bridging required, restart edoxaban 24-48 hours post-operatively
High-risk medicines Explanation: ***Stop edoxaban now, give PCC for reversal, start warfarin post-operatively with LMWH bridge***
- This patient requires a **mechanical mitral valve replacement**, which is a **contraindication** for **Direct Oral Anticoagulants (DOACs)** like edoxaban due to the high risk of valve thrombosis and systemic embolism.
- For urgent surgery (48 hours) with a DOAC, immediate cessation is required. **Prothrombin Complex Concentrate (PCC)** can be considered for rapid reversal, and post-operatively, the patient must be transitioned to **warfarin** (a Vitamin K antagonist) with a **low molecular weight heparin (LMWH) bridge** until the INR is therapeutic.
*Continue edoxaban until 24 hours before surgery, then restart 6 hours post-operatively*
- Continuing edoxaban until 24 hours before major cardiac surgery carries a significant **bleeding risk**, as the drug's anticoagulant effect may still be present during the procedure.
- **Restarting edoxaban** post-operatively is inappropriate because DOACs are not recommended for patients with **mechanical heart valves** due to increased thrombotic events.
*Stop edoxaban 48 hours before surgery, bridge with LMWH, restart edoxaban post-operatively*
- While stopping edoxaban 48 hours before surgery is appropriate for some procedures, **restarting edoxaban** is incorrect for a patient with a new **mechanical heart valve**.
- **DOACs** have shown **inferiority to warfarin** and increased adverse events in clinical trials (e.g., RE-ALIGN trial with dabigatran) for mechanical heart valve prophylaxis.
*Stop edoxaban now, start intravenous heparin infusion, restart edoxaban post-operatively*
- While **intravenous heparin** could serve as a perioperative bridge, the plan to **restart edoxaban** post-operatively is fundamentally flawed.
- Patients with **mechanical mitral valves** require **warfarin** for long-term anticoagulation, targeting a specific INR range (e.g., 2.5-3.5) to prevent thrombosis.
*Stop edoxaban now, no bridging required, restart edoxaban 24-48 hours post-operatively*
- Immediately stopping edoxaban is correct, but **no bridging** pre- or post-operatively (until warfarin is therapeutic) for a mechanical valve places the patient at a very high risk of **valve thrombosis** and thromboembolic events.
- **Restarting edoxaban** is definitively incorrect as it is contraindicated for **mechanical heart valves**.
High-risk medicines UK Medical PG Question 8: A 52-year-old woman with type 2 diabetes is established on insulin glargine 42 units at bedtime and metformin 1g twice daily. She is about to commence treatment for latent tuberculosis with rifampicin 600mg daily for 3 months. What is the most important consideration regarding her diabetes management?
- A. Rifampicin has no effect on insulin requirements
- B. Rifampicin may increase insulin requirements significantly due to enzyme induction (Correct Answer)
- C. Rifampicin may decrease insulin requirements due to improved insulin sensitivity
- D. Metformin dose should be reduced due to interaction with rifampicin
- E. Insulin glargine should be switched to NPH insulin due to rifampicin interaction
High-risk medicines Explanation: ***Rifampicin may increase insulin requirements significantly due to enzyme induction***- Rifampicin is a potent **CYP450 enzyme inducer**, accelerating the metabolism of endogenous hormones like cortisol, leading to increased **insulin resistance**.- This increased resistance necessitates a **higher dose of insulin** to maintain glycemic control, often requiring careful monitoring and dose adjustments. *Rifampicin has no effect on insulin requirements*- This is incorrect as rifampicin significantly impacts **glucose metabolism** by inducing hepatic enzymes, which alters the clearance of substances affecting blood glucose.- Due to its **enzyme-inducing properties**, rifampicin frequently leads to hyperglycemia and increased insulin requirements in diabetic patients. *Rifampicin may decrease insulin requirements due to improved insulin sensitivity*- Rifampicin does not improve **insulin sensitivity**; rather, its effects on drug metabolism typically lead to increased insulin resistance.- A decrease in insulin requirements is usually associated with conditions like **renal impairment** or drugs that enhance insulin sensitivity, which is not the case here. *Metformin dose should be reduced due to interaction with rifampicin*- Rifampicin can induce transporters involved in **metformin uptake and elimination**, potentially *decreasing* metformin's plasma concentration and efficacy, not increasing toxicity.- Therefore, a **reduction in metformin dose** is not indicated; the primary concern remains the increased insulin resistance and need for more insulin. *Insulin glargine should be switched to NPH insulin due to rifampicin interaction*- There is no clinical or pharmacological basis to switch from **insulin glargine** (a long-acting basal insulin) to NPH insulin due to rifampicin co-administration.- The type of basal insulin is less relevant than the overall **insulin dosage**, which needs to be adjusted upwards to counteract rifampicin-induced insulin resistance.
High-risk medicines UK Medical PG Question 9: A 71-year-old man with mechanical mitral valve replacement is on warfarin (target INR 2.5-3.5). He requires urgent colonoscopy for suspected lower GI bleeding. His current INR is 3.2. The procedure is needed within 12 hours. What is the most appropriate management of his anticoagulation?
- A. Omit warfarin doses and proceed when INR <1.5
- B. Give intravenous vitamin K 5mg and proceed when INR <1.5 (Correct Answer)
- C. Give oral vitamin K 1-2mg and proceed when INR <1.5
- D. Give prothrombin complex concentrate (PCC) and proceed immediately
- E. Proceed with colonoscopy at current INR of 3.2
High-risk medicines Explanation: ***Give intravenous vitamin K 5mg and proceed when INR <1.5***- **Intravenous vitamin K** is appropriate for urgent reversal when a procedure is required within **6-12 hours**, as it provides a predictable and sustained reduction in INR.- For a colonoscopy, especially with potential for biopsy or polypectomy, an INR of **less than 1.5** is generally required to minimize the risk of significant procedural bleeding.*Omit warfarin doses and proceed when INR <1.5*- Simply **withholding warfarin** doses is too slow for an urgent situation, as the INR would typically take **3 to 5 days** to normalize sufficiently.- This approach is appropriate for **elective procedures** with no immediate clinical concern, not for suspected active lower GI bleeding within 12 hours.*Give oral vitamin K 1-2mg and proceed when INR <1.5*- **Oral vitamin K** has a slower onset of action than the intravenous route, typically taking **12 to 24 hours** to effectively lower the INR, which is too long for a procedure needed within 12 hours.- It is generally reserved for patients with an **elevated INR** and no significant bleeding who are not requiring urgent surgical intervention.*Give prothrombin complex concentrate (PCC) and proceed immediately*- **Prothrombin complex concentrate (PCC)** is reserved for **life-threatening bleeding** or emergency surgery that cannot wait, as it carries a higher risk of **thromboembolic events**.- While it acts immediately, the urgent need for a colonoscopy for suspected bleeding (not active life-threatening hemorrhage) does not usually warrant the higher risks associated with PCC, especially in a patient with a **mechanical mitral valve**.*Proceed with colonoscopy at current INR of 3.2*- Performing an invasive procedure like a colonoscopy at a therapeutic INR of 3.2 is contraindicated due to the high risk of **uncontrolled hemorrhage**, particularly with suspected GI bleeding.- Practice guidelines require the INR to be corrected to near-normal levels before performing high-risk endoscopic procedures to ensure **hemostasis** and patient safety.
High-risk medicines UK Medical PG Question 10: A 63-year-old man with type 1 diabetes is admitted with severe diabetic ketoacidosis (pH 7.08, ketones 5.2 mmol/L, glucose 28 mmol/L). He is commenced on a fixed-rate intravenous insulin infusion at 0.1 units/kg/hour and receives fluid resuscitation. After 4 hours, his glucose has fallen to 14 mmol/L but ketones remain at 4.8 mmol/L and pH is 7.15. What is the most appropriate next step in his insulin management?
- A. Reduce insulin infusion rate to 0.05 units/kg/hour as glucose is improving
- B. Continue current insulin infusion rate and add 10% glucose infusion (Correct Answer)
- C. Stop insulin infusion and switch to subcutaneous basal-bolus regimen
- D. Increase insulin infusion rate to 0.15 units/kg/hour to accelerate ketone clearance
- E. Continue current insulin infusion without adding glucose
High-risk medicines Explanation: ***Continue current insulin infusion rate and add 10% glucose infusion***
- In **Diabetic Ketoacidosis (DKA)**, the primary goal of insulin is to suppress **ketogenesis**; therefore, the fixed-rate insulin infusion must be maintained until **ketones** are cleared (<0.6 mmol/L).
- Adding **10% glucose** prevents hypoglycemia once blood glucose levels fall below **14 mmol/L**, allowing the insulin infusion to continue safely until metabolic resolution is achieved.
*Reduce insulin infusion rate to 0.05 units/kg/hour as glucose is improving*
- Reducing the insulin dose prematurely slows the rate of **ketone clearance** and can lead to a rebound in acidosis.
- The **fixed-rate intravenous insulin infusion (FRIII)** should remain at **0.1 units/kg/hour** regardless of glucose changes until the DKA is fully resolved.
*Stop insulin infusion and switch to subcutaneous basal-bolus regimen*
- Transitioning to **subcutaneous insulin** is only appropriate when the patient can eat and drink, and biochemical markers show **metabolic resolution** (pH >7.3, ketones <0.6 mmol/L).
- Stopping intravenous insulin while the patient is still in **acidosis** with persistent ketonemia will result in clinical deterioration.
*Increase insulin infusion rate to 0.15 units/kg/hour to accelerate ketone clearance*
- The recommended starting rate of **0.1 units/kg/hour** is generally sufficient to achieve the required rate of **ketone reduction** (at least 0.5 mmol/L/hour).
- Increasing the rate is only indicated if the **ketone levels** fail to fall adequately after the first hour of treatment, which is not clearly the case here as pH has shown slight improvement.
*Continue current insulin infusion without adding glucose*
- Continuing insulin without adding a **dextrose source** when glucose reaches **14 mmol/L** carries a high risk of **iatrogenic hypoglycemia**.
- Substrate in the form of **intravenous glucose** is necessary to maintain euglycemia while the high-dose insulin works to switch off **fatty acid metabolism**.
More High-risk medicines UK Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
